Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: A controlled study

Zincir, Serkan; Zincir, Selma Bozkurt; Doruk, Ali; Erdem, Murat; Çeli̇k, Cemi̇l; Ak, Mehmet; Garip, Beyazıt; Yükselir, Cihad; Karaahmetoğlu, Bülent

doi:10.1016/j.psychres.2014.07.013

Cited by 18 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies using HPLC provided noticeably higher ADMA levels. In the case of the study published by Zincir et al, the correct separation of asymmetric dimethylarginine from symmetric dimethylarginine can be doubted, however, ADMA and SDMA levels are presented separately [31]. Turkcuoglu et al obtained nearly double plasma ADMA concentration as referred to in the methodological instructions of the kit that they have used; nevertheless, the possible reason for this is not discussed by the Authors [32].…”

Section: Discussionmentioning

confidence: 99%

The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

BackgroundAsymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase, marker and mediator of endothelial dysfunction. Several studies have demonstrated its value in cardiovascular risk stratification and all-cause mortality prediction. The aim was to determine the reference range of plasma ADMA in healthy adults.Methods and resultsTaking into account the most widely used ADMA measurement methods, only studies using either high performance liquid chromatography (HPLC) -with fluorescence or mass spectrometric detection-, or enzyme-linked immunosorbent assay (ELISA) to quantify plasma ADMA concentrations were enrolled. 66 studies were included in the quantitative analysis (24 using ELISA and 42 using HPLC) reporting a total number of 5528 non-diabetic, non-hypertensive, non-obese adults without any medication (3178 men and 2350 women, 41.6 ± 16.9 years old). The reference range of ADMA (in μmol/l with 95% confidence interval in parenthesis) was 0.34 (0.29–0.38)– 1.10 (0.85–1.35) with a mean of 0.71 (0.57–0.85) (n = 4093) measured by HPLC and 0.25 (0.18–0.31)– 0.92 (0.76–1.09) with a mean of 0.57 (0.48–0.66) (n = 1435) by ELISA.ConclusionsNumerous publications suggested that asymmetric dimethylarginine is not only an outstanding tool of disease outcome prediction but also a new potential therapeutic target substance; the reference range provided by this meta-analysis can become of great importance and aid to further investigations. However, developing a standard measurement method would be beneficial to facilitate the clinical usage of ADMA.

show abstract

Section: Discussionmentioning

confidence: 99%

The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Interessant in dem Zusammenhang erscheinen auch die Arbeiten, die eine Verbindung zwischen einen gestörten Stickstoff (NO-) Stoffwechsel und Kleinwuchs einerseits [28] und andererseits einer schizophrenen Erkrankung aufzeigen [29]. In der Arbeit von Langen et al 2015 [28] zeigte sich bei Kleinwüchsigen mit und ohne Wachstumshormonmangel eine Erhöhung der Aminosäure Homoarginin als auch des ADMA's.…”

Section: Neurobiologie Genetik Und Neuroendokrinologieunclassified

“…ADMA (=Asymmetric dimethylarginine) ist ein Antagonist der NO-Synthase, der einen negativen Einfluss auf die Bereitstellung von Stickstoffmonoxyd und somit auf das Körperwachstum hat. Deutlich reduzierte ADMA-Spiegel fanden sich in der Untersuchung von Zincir et al [29] an 49 an einer schizophrenen Psychose ersterkrankten männlichen Patienten im Vergleich zu gesunden Kontrollen. Erwähnenswert dabei ist, dass die ADMA-Spiegel nach einer 2 monatigen antipsychotischen Behandlung der Patienten niedriger und der Kontrollgruppe näher ausfielen.…”

Section: Neurobiologie Genetik Und Neuroendokrinologieunclassified

Psychiatrische Komorbidität beim Ullrich-Turner-Syndrom

Mavrogiorgou

Irawan

Lücke

et al. 2018

Fortschr Neurol Psychiatr

View full text Add to dashboard Cite

Zusammenfassung Ziel Das Ullrich-Turner Syndrom (UTS) ist eine X-chromosomale Störung, deren klinische Symptomatik vielfältig und heterogen ist. Neuropsychiatrische Erkrankungen zählen jedoch nicht zu den typischen Komorbiditäten des Turner-Syndrom, allerdin gs liegen mittlerweile mehrere Berichte in Form von Einzellfalldarstellungen vor. Methodik Anhand der Darstellung des Falls einer Patientin mit einem Turner-Syndrom und einer schizoaffektiven Störung werden mögliche Zusammenhänge und die dazu vorhandene Literatur diskutiert. Schlussfolgerung Die gehäuften Berichte über das zusätzliche Auftreten einer psychotischen Symptomatik beim UTS legen einen Zusammenhang zwischen der X-chromosomalen Aberration und einer Erkrankungen aus dem schizophrenen Formenkreis nahe. Hinsichtlich der Komorbidität bedarf es jedoch einer allgemeingültigen nosologischen Kategorisierung, die auch eine weitere notwendige Forschungsaktivität erleichtern würde.

show abstract

“…Şizofreni hastalarında L-arjinin metabolizmasının hastalık sürecinin uzunluğu ile ilişkili olduğunu öne süren çalışmaların (Tomiya ve ark. 2007) yanı sıra ilk rahatsızlık dönemindeki hastalarda dahi arjinin metabolizmasında değişiklikler olduğunu gösteren çalış-malar mevcuttur (Zincir ve ark. 2014, Misiak ve ark.…”

Section: Introductionunclassified

L-Arginine Add-On Treatment for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Koçyiğit¹,

Yoca²,

Karahan³

et al. 2017

Turkish Journal of Psychiatry

View full text Add to dashboard Cite

ÖZETAmaç: Şizofrenide mevcut ilaç tedavileri kısmen etkili olduğundan güçlendirme veya kombinasyon tedavileri sık olarak uygulanmaktadır. Nitrik oksitin (NO) şizofreninin fizyopatolojisinde rol oynadığı öne sürülmektedir. L-arjinin NO öncülü olan bir esansiyel aminoasittir. Bu çalışmada şizofreni veya şizoafektif bozukluk tanısı konmuş klinik belirtileri kısmen devam eden hastaların mevcut tedavilerine eklenen L-arjinin'in, şizofreninin pozitif, negatif ve depresif belirtileri üzerindeki etkisinin incelemesi amaçlanmıştır.Yöntem: Çalışmaya 12 şizofreni veya şizoafektif bozukluk tanısı konmuş hasta dahil edilmiştir. Hastaların mevcut tedavilerine günde iki kez 3 g L-arjinin rastgele, çift kör, plasebo kontrollü ve çapraz geçişli şekilde eklenmiştir. Üç haftalık tedavi döneminin ardından 7 günlük ilaçsız dö-nem ve daha sonra ikinci 3 haftalık tedavi dönemine geçilmiştir. Current drug treatments for schizophrenia are only partially effective and combination/augmentation strategies are commonly used. Nitric Oxide (NO) may play a role in the pathophysiology of schizophrenia. L-arginine is the precursor of NO. In this study, we aimed to investigate whether L-arginine add-on to current medication might improve positive, negative, and depressive symptoms in schizophrenia/ schizoaffective disorder patients in partial remission. Method:The study was designed as a randomized, double-blind, placebo-controlled, crossover study of L-arginine 3 g b.i.d. as an add-on treatment to the patients' usual medication. Twelve patients diagnosed with schizophrenia/schizoaffective disorder were included. The duration of the treatment was 3 weeks, with a wash-out period of 7 days before alternation for the second arm. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS), and the Clinical Global Impression (CGI) scales. Results: Our analyses revealed that L-arginine 6 g/day add-on to usual treatment was not superior to placebo for positive, negative, and depressive symptoms associated with schizophrenia as assessed with PANSS, CDSS and CGI scales. Conclusion:In our study, L-arginine did not seem to have an effect on schizophrenia symptoms. Studies with a larger sample size, with higher doses of L-arginine, and with a longer duration are needed for a definite conclusion.

show abstract

Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: A controlled study

Cited by 18 publications

References 17 publications

The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis

The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis

Psychiatrische Komorbidität beim Ullrich-Turner-Syndrom

L-Arginine Add-On Treatment for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Contact Info

Product

Resources

About